CRA Reports Q1 Revenue of $201M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Reports Q1 revenue $201M, consensus $193.82M. "Maintaining the momentum of a record fiscal 2025, CRA continued its strong performance into the first quarter of fiscal 2026 as revenue increased by 10.5% year over year to $201.0 million," said Paul Maleh, CRA's President and Chief Executive Officer. "This represents the highest quarterly revenue in the company's history, besting the previous record set by the fourth quarter of fiscal 2025. Broad-based contributions drove the quarter's strong performance, with eight practices growing year over year. Four practices-Energy, Finance, Forensic Services, and Life Sciences-posted double-digit revenue growth, while the Antitrust & Competition Economics practice posted a new high for quarterly revenue. This strong practice performance reflected balanced growth across our portfolio, as our Legal & Regulatory offerings grew 11.5% year over year and Management Consulting offerings expanded 8.3%. We also generated growth across our geographies, with our North American operations increasing revenue by 8.5% and our international operations expanding 20.3% year over year."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRAI
Wall Street analysts forecast CRAI stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 149.950
Low
245.00
Averages
245.00
High
245.00
Current: 149.950
Low
245.00
Averages
245.00
High
245.00
About CRAI
CRA International, Inc. is a global consulting firm specializing in providing economic, financial and management consulting services. It offers consulting services in two areas: litigation, regulatory, and financial consulting and management consulting. It provides consulting services to corporate clients and attorneys in a range of litigation and regulatory proceedings, providing research and analysis, expert testimony, and support in litigation and regulatory proceedings in all areas of finance, accounting, economics, insurance, and forensic accounting and investigations. It also uses its expertise in economics, finance, and business to offer law firms, businesses, and government agencies services. Its management consulting services include strategy development, performance improvement, corporate strategy and portfolio analysis, estimation of market demand, new product pricing strategies, survey and market research, valuation of intellectual property and other assets and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BriaCell Engages CRA for Bria-IMT Market Evaluation
- Market Evaluation Partnership: BriaCell Therapeutics has engaged Charles River Associates (CRA) and Kaleio, Inc. to evaluate the epidemiology, pricing, and prescriber dynamics of Bria-IMT in the metastatic breast cancer market, thereby supporting brand strategies and enhancing market access potential.
- Clinical Trial Progress: Bria-IMT is currently under evaluation in BriaCell's pivotal Phase 3 study, with ClinicalTrials.gov identifier NCT06072612, and is not yet commercially approved, laying the groundwork for future commercialization planning.
- Commercial Readiness: This collaboration is viewed as a prudent step for BriaCell as it continues to assess Bria-IMT while preparing for potential commercialization discussions, indicating the company's focus on future market opportunities.
- Innovative Treatment Development: BriaCell is dedicated to developing novel immunotherapies to transform cancer care, and as the evaluation of Bria-IMT progresses, it may present new growth opportunities for the company, further enhancing its competitiveness in the biotechnology sector.
See More
BriaCell Engages CRA and Kaleio for Market Access Evaluation of Bria-IMT
- Market Evaluation Partnership: BriaCell Therapeutics has engaged Charles River Associates and Kaleio, Inc. to assess the pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer, thereby supporting brand strategies and commercial readiness solutions.
- Clinical Trial Progress: Bria-IMT is currently undergoing a pivotal Phase 3 clinical study (ClinicalTrials.gov identifier: NCT06072612), and while it is not yet commercially approved, the success of this study could pave the way for future market access.
- Commercial Readiness Steps: This collaboration is viewed as a prudent step by BriaCell as it continues to evaluate Bria-IMT and prepares for potential commercialization planning and strategic discussions, reflecting the company's focus on future market opportunities.
- Innovative Treatment Development: BriaCell is dedicated to developing novel immunotherapies to transform cancer care, and as Bria-IMT progresses through clinical trials, the company's competitive position and industry impact are expected to significantly enhance.
See More
CRAI Dividend Forecast and Stock Performance Analysis
- Dividend Yield Analysis: CRAI's current estimated annualized dividend yield stands at 1.54%, and while dividends are not always predictable, historical data aids in assessing the likelihood of future dividends, thereby influencing investor return expectations.
- Stock Price Range: CRAI's 52-week low is $132.17 and its high is $227.29, with the last trade at $148.89, indicating significant price fluctuations that may affect investor buying decisions based on perceived value.
- Recent Stock Performance: On Friday, CRAI shares rose approximately 0.2%, reflecting short-term market confidence in the stock, which could attract more investor interest and potentially drive further price appreciation.
- Technical Indicator Reference: Comparing the stock's performance against the 200-day moving average provides investors with a technical analysis framework, assisting them in evaluating CRAI's future trajectory and optimal investment timing.
See More
U.S. Producer Price Index Surges, Impacting Stocks
- Producer Price Surge: The U.S. Bureau of Labor Statistics reported a 1.4% month-over-month increase in the Producer Price Index (PPI) for April, marking the largest monthly rise since March 2022, with a year-over-year increase of 6%, indicating persistent inflationary pressures that may lead companies to pass costs onto consumers, thereby increasing market uncertainty.
- Market Reaction: Following this news, several stocks fell sharply, including CRA down 3.5%, SAIC down 4.5%, OSI Systems down 4.2%, EPAM down 3.9%, and Kyndryl down 4.8%, reflecting the market's sensitive response to inflation data and its implications for future earnings.
- Kyndryl's Volatility: Kyndryl's shares have experienced over 20 moves greater than 5% in the past year, and while today's drop is significant, it suggests that the market perceives the news as impactful but not fundamentally altering its view of the business, indicating investor confidence in long-term contracts.
- Investor Interest in IT Sector: As the threat of prolonged Middle East conflict recedes, enterprise clients are more likely to commit to multi-year digital transformation projects, and with moderating inflation expectations alongside falling oil prices, IT firms can better forecast wage and overhead expenses, driving renewed investor interest in the sector as a reliable growth play.
See More
CRA International Q1 Earnings Exceed Expectations
- Earnings Performance: CRA International reported a Q1 Non-GAAP EPS of $1.99, missing expectations by $0.03; however, revenue reached $201.0 million, reflecting a 10.5% year-over-year increase and exceeding forecasts by $7.18 million, indicating robust growth in the market.
- Revenue Target: The company outlined a revenue target of $785 million to $805 million for 2026, demonstrating confidence in future growth, particularly through ongoing investments in AI-driven consulting services.
- Profitability Analysis: Although the Q1 Non-GAAP EPS was $2.06, slightly missing expectations by $0.01, the revenue of $197 million surpassed forecasts by $6.46 million, showcasing the company's ability to maintain strong profitability in a competitive landscape.
- Market Rating: Seeking Alpha's Quant Rating on CRA International reflects a positive outlook from the market regarding its future performance, further bolstering investor confidence in the company's strategic direction.
See More
CRA International Stock Options Show High Implied Volatility
- Options Market Volatility: The $135 call option for CRA International expiring on May 15, 2026, shows high implied volatility, indicating that the market anticipates significant price movement, potentially due to an upcoming event, warranting investor attention.
- Analyst Estimate Changes: Over the past 60 days, two analysts have raised their earnings estimates for CRA International to $2.06 per share, reflecting a cautiously optimistic outlook on the company's future performance amidst fluctuating expectations.
- Trading Strategy Impact: The high implied volatility attracts options traders, with many seasoned traders opting to sell options to capture time decay, hoping that the underlying stock will not move as much as initially expected by expiration.
- Investor Focus: CRA International has been highlighted in a recent Zacks Investment Research report as a potential trading opportunity, which, combined with its ranking in the consulting services industry, may draw increased investor interest.
See More
BriaCell Engages CRA for Bria-IMT Market Evaluation
- Market Evaluation Partnership: BriaCell Therapeutics has engaged Charles River Associates (CRA) and Kaleio, Inc. to evaluate the epidemiology, pricing, and prescriber dynamics of Bria-IMT in the metastatic breast cancer market, thereby supporting brand strategies and enhancing market access potential.
- Clinical Trial Progress: Bria-IMT is currently under evaluation in BriaCell's pivotal Phase 3 study, with ClinicalTrials.gov identifier NCT06072612, and is not yet commercially approved, laying the groundwork for future commercialization planning.
- Commercial Readiness: This collaboration is viewed as a prudent step for BriaCell as it continues to assess Bria-IMT while preparing for potential commercialization discussions, indicating the company's focus on future market opportunities.
- Innovative Treatment Development: BriaCell is dedicated to developing novel immunotherapies to transform cancer care, and as the evaluation of Bria-IMT progresses, it may present new growth opportunities for the company, further enhancing its competitiveness in the biotechnology sector.
See More
BriaCell Engages CRA and Kaleio for Market Access Evaluation of Bria-IMT
- Market Evaluation Partnership: BriaCell Therapeutics has engaged Charles River Associates and Kaleio, Inc. to assess the pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer, thereby supporting brand strategies and commercial readiness solutions.
- Clinical Trial Progress: Bria-IMT is currently undergoing a pivotal Phase 3 clinical study (ClinicalTrials.gov identifier: NCT06072612), and while it is not yet commercially approved, the success of this study could pave the way for future market access.
- Commercial Readiness Steps: This collaboration is viewed as a prudent step by BriaCell as it continues to evaluate Bria-IMT and prepares for potential commercialization planning and strategic discussions, reflecting the company's focus on future market opportunities.
- Innovative Treatment Development: BriaCell is dedicated to developing novel immunotherapies to transform cancer care, and as Bria-IMT progresses through clinical trials, the company's competitive position and industry impact are expected to significantly enhance.
See More
CRAI Dividend Forecast and Stock Performance Analysis
- Dividend Yield Analysis: CRAI's current estimated annualized dividend yield stands at 1.54%, and while dividends are not always predictable, historical data aids in assessing the likelihood of future dividends, thereby influencing investor return expectations.
- Stock Price Range: CRAI's 52-week low is $132.17 and its high is $227.29, with the last trade at $148.89, indicating significant price fluctuations that may affect investor buying decisions based on perceived value.
- Recent Stock Performance: On Friday, CRAI shares rose approximately 0.2%, reflecting short-term market confidence in the stock, which could attract more investor interest and potentially drive further price appreciation.
- Technical Indicator Reference: Comparing the stock's performance against the 200-day moving average provides investors with a technical analysis framework, assisting them in evaluating CRAI's future trajectory and optimal investment timing.
See More
U.S. Producer Price Index Surges, Impacting Stocks
- Producer Price Surge: The U.S. Bureau of Labor Statistics reported a 1.4% month-over-month increase in the Producer Price Index (PPI) for April, marking the largest monthly rise since March 2022, with a year-over-year increase of 6%, indicating persistent inflationary pressures that may lead companies to pass costs onto consumers, thereby increasing market uncertainty.
- Market Reaction: Following this news, several stocks fell sharply, including CRA down 3.5%, SAIC down 4.5%, OSI Systems down 4.2%, EPAM down 3.9%, and Kyndryl down 4.8%, reflecting the market's sensitive response to inflation data and its implications for future earnings.
- Kyndryl's Volatility: Kyndryl's shares have experienced over 20 moves greater than 5% in the past year, and while today's drop is significant, it suggests that the market perceives the news as impactful but not fundamentally altering its view of the business, indicating investor confidence in long-term contracts.
- Investor Interest in IT Sector: As the threat of prolonged Middle East conflict recedes, enterprise clients are more likely to commit to multi-year digital transformation projects, and with moderating inflation expectations alongside falling oil prices, IT firms can better forecast wage and overhead expenses, driving renewed investor interest in the sector as a reliable growth play.
See More
CRA International Q1 Earnings Exceed Expectations
- Earnings Performance: CRA International reported a Q1 Non-GAAP EPS of $1.99, missing expectations by $0.03; however, revenue reached $201.0 million, reflecting a 10.5% year-over-year increase and exceeding forecasts by $7.18 million, indicating robust growth in the market.
- Revenue Target: The company outlined a revenue target of $785 million to $805 million for 2026, demonstrating confidence in future growth, particularly through ongoing investments in AI-driven consulting services.
- Profitability Analysis: Although the Q1 Non-GAAP EPS was $2.06, slightly missing expectations by $0.01, the revenue of $197 million surpassed forecasts by $6.46 million, showcasing the company's ability to maintain strong profitability in a competitive landscape.
- Market Rating: Seeking Alpha's Quant Rating on CRA International reflects a positive outlook from the market regarding its future performance, further bolstering investor confidence in the company's strategic direction.
See More
CRA International Stock Options Show High Implied Volatility
- Options Market Volatility: The $135 call option for CRA International expiring on May 15, 2026, shows high implied volatility, indicating that the market anticipates significant price movement, potentially due to an upcoming event, warranting investor attention.
- Analyst Estimate Changes: Over the past 60 days, two analysts have raised their earnings estimates for CRA International to $2.06 per share, reflecting a cautiously optimistic outlook on the company's future performance amidst fluctuating expectations.
- Trading Strategy Impact: The high implied volatility attracts options traders, with many seasoned traders opting to sell options to capture time decay, hoping that the underlying stock will not move as much as initially expected by expiration.
- Investor Focus: CRA International has been highlighted in a recent Zacks Investment Research report as a potential trading opportunity, which, combined with its ranking in the consulting services industry, may draw increased investor interest.
See More
